AU2017253241B2 - Compositions and methods for making antibodies based on use of expression-enhancing loci - Google Patents

Compositions and methods for making antibodies based on use of expression-enhancing loci Download PDF

Info

Publication number
AU2017253241B2
AU2017253241B2 AU2017253241A AU2017253241A AU2017253241B2 AU 2017253241 B2 AU2017253241 B2 AU 2017253241B2 AU 2017253241 A AU2017253241 A AU 2017253241A AU 2017253241 A AU2017253241 A AU 2017253241A AU 2017253241 B2 AU2017253241 B2 AU 2017253241B2
Authority
AU
Australia
Prior art keywords
rrs
vector
nucleotide sequence
cell
locus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017253241A
Other languages
English (en)
Other versions
AU2017253241A1 (en
Inventor
Robert Babb
Darya Burakov
Gang Chen
James P. Fandl
Yu Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2017253241A1 publication Critical patent/AU2017253241A1/en
Application granted granted Critical
Publication of AU2017253241B2 publication Critical patent/AU2017253241B2/en
Priority to AU2024220124A priority Critical patent/AU2024220124A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2017253241A 2016-04-20 2017-04-20 Compositions and methods for making antibodies based on use of expression-enhancing loci Active AU2017253241B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024220124A AU2024220124A1 (en) 2016-04-20 2024-09-26 Compositions and methods for making antibodies based on use of expression-enhancing loci

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662325400P 2016-04-20 2016-04-20
US62/325,400 2016-04-20
PCT/US2017/028555 WO2017184832A1 (en) 2016-04-20 2017-04-20 Compositions and methods for making antibodies based on use of expression-enhancing loci

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024220124A Division AU2024220124A1 (en) 2016-04-20 2024-09-26 Compositions and methods for making antibodies based on use of expression-enhancing loci

Publications (2)

Publication Number Publication Date
AU2017253241A1 AU2017253241A1 (en) 2018-09-20
AU2017253241B2 true AU2017253241B2 (en) 2024-07-04

Family

ID=58701851

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017253241A Active AU2017253241B2 (en) 2016-04-20 2017-04-20 Compositions and methods for making antibodies based on use of expression-enhancing loci
AU2024220124A Pending AU2024220124A1 (en) 2016-04-20 2024-09-26 Compositions and methods for making antibodies based on use of expression-enhancing loci

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024220124A Pending AU2024220124A1 (en) 2016-04-20 2024-09-26 Compositions and methods for making antibodies based on use of expression-enhancing loci

Country Status (15)

Country Link
US (2) US11512144B2 (enExample)
EP (1) EP3445781A1 (enExample)
JP (4) JP7096770B2 (enExample)
KR (3) KR102906454B1 (enExample)
CN (2) CN109195986B (enExample)
AR (1) AR109451A1 (enExample)
AU (2) AU2017253241B2 (enExample)
BR (1) BR112018071283A2 (enExample)
CA (1) CA3015389A1 (enExample)
EA (1) EA201892010A1 (enExample)
IL (2) IL262266B2 (enExample)
MX (2) MX2018012868A (enExample)
SG (2) SG10202010155YA (enExample)
TW (2) TW202415767A (enExample)
WO (1) WO2017184832A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018012868A (es) 2016-04-20 2019-03-11 Regeneron Pharma Composiciones y metodos para generar anticuerpos basado en el uso de loci potenciadores de expresion.
IL275462B2 (en) * 2017-12-22 2026-01-01 Genentech Inc Targeted integration of nucleic acids
CN113631711B (zh) * 2018-12-21 2025-03-04 豪夫迈·罗氏有限公司 核酸的靶向整合
EP3950938A4 (en) * 2019-04-02 2023-01-18 Chugai Seiyaku Kabushiki Kaisha PROCEDURE FOR INTRODUCING A TARGET-SPECIFIC ALIEN
AU2020308002A1 (en) * 2019-06-26 2022-01-20 Genentech, Inc. Randomized configuration targeted integration of nucleic acids
US20230304062A1 (en) 2021-10-18 2023-09-28 Regeneron Pharmaceuticals, Inc. Controlled transcription of polynucleotides
US12234472B2 (en) 2021-10-18 2025-02-25 Regeneron Pharmaceuticals, Inc. Eukaryotic cells comprising adenovirus-associated virus polynucleotides
TW202334402A (zh) 2021-10-18 2023-09-01 美商再生元醫藥公司 包含整合ｃａｓ９基因以產生穩定整合位點的哺乳動物細胞，以及包含穩定整合位點及其他位點的哺乳動物細胞
EP4453227A1 (en) * 2021-12-22 2024-10-30 Genentech, Inc. Multi-vector recombinase mediated cassette exchange
US20250361524A1 (en) * 2022-06-10 2025-11-27 Fujifilm Diosynth Biotechnologies Uk Limited Method for producing cells, method for producing heteromultimeric protein, method for producing bispecific antibody, and method for producing vector set, mammalian cells, CHO cells, and cell pool
CN121794393A (zh) 2023-09-07 2026-04-03 里珍纳龙药品有限公司 经共价表面修饰的腺相关病毒的生产和纯化
TW202540433A (zh) 2023-11-21 2025-10-16 美商再生元醫藥公司 藉由活體外接合產生共價表面修飾之腺相關病毒及共價表面修飾的腺相關病毒之純化
WO2026050618A1 (en) 2024-08-29 2026-03-05 Regeneron Pharmaceuticals, Inc. Polynucleotide constructs and cell lines for recombinant aav production

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6800457B2 (en) 1998-09-22 2004-10-05 Bristol-Myers Squibb Company Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6406863B1 (en) 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
AU2003237259B2 (en) 2002-05-29 2008-01-24 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
CA2504595A1 (en) 2002-11-14 2004-06-03 Lynne Krummen Intron fusion construct and method of using for selecting high-expressing production cell lines
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
WO2007110205A2 (en) 2006-03-24 2007-10-04 Merck Patent Gmbh Engineered heterodimeric protein domains
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
WO2008079943A2 (en) 2006-12-21 2008-07-03 Smithkline Beecham Corporation Novel methods
US20080216185A1 (en) 2007-01-19 2008-09-04 Invitrogen Corporation Compositions and Methods for Genetic Manipulation and Monitoring of Cell Lines
CN104497143B (zh) 2007-03-29 2020-08-25 健玛保 双特异性抗体及其制造方法
WO2008151219A1 (en) * 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US8409838B2 (en) * 2009-06-02 2013-04-02 Regeneron Pharmaceuticals, Inc. Fucosylation-deficient cells
LT2975051T (lt) 2009-06-26 2021-07-12 Regeneron Pharmaceuticals, Inc. Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
MX2012003396A (es) 2009-09-16 2012-04-10 Genentech Inc Complejos de proteina conteniendo helice super-enrollada y/o enlazador tether y usos de los mismos.
CN102575264A (zh) 2009-09-18 2012-07-11 瑟莱克斯公司 增加的转基因表达和加工的产品和方法
JP6040148B2 (ja) 2010-04-20 2016-12-07 ゲンマブ エー／エス ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
AU2011290480B2 (en) 2010-08-16 2015-07-30 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
CN104011080B (zh) 2011-12-22 2017-10-20 弗·哈夫曼-拉罗切有限公司 用于真核细胞的全长抗体展示系统及其用途
TWI641687B (zh) 2012-05-29 2018-11-21 美商再生元醫藥公司 生產細胞株增強子
EP2711428A1 (en) * 2012-09-21 2014-03-26 Lonza Biologics plc. Site-specific integration
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TW202423993A (zh) 2012-11-14 2024-06-16 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
TWI682941B (zh) * 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
TWI670283B (zh) 2013-12-23 2019-09-01 美商建南德克公司 抗體及使用方法
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
MX2017005306A (es) * 2014-10-23 2018-01-09 Regeneron Pharma Novedosos sitios de integracion en celulas cho y usos de estos.
KR102777500B1 (ko) 2015-09-23 2025-03-11 리제너론 파아마슈티컬스, 인크. 최적화된 항-cd3 이중특이적 항체 및 이의 용도
MX2018012868A (es) * 2016-04-20 2019-03-11 Regeneron Pharma Composiciones y metodos para generar anticuerpos basado en el uso de loci potenciadores de expresion.

Also Published As

Publication number Publication date
AU2017253241A1 (en) 2018-09-20
US11512144B2 (en) 2022-11-29
MX2025003852A (es) 2025-05-02
SG11201807885PA (en) 2018-10-30
TW202415767A (zh) 2024-04-16
IL314779A (en) 2024-10-01
SG10202010155YA (en) 2020-11-27
IL262266A (en) 2018-11-29
JP2021164479A (ja) 2021-10-14
US20190233544A1 (en) 2019-08-01
US12528883B2 (en) 2026-01-20
TW201803986A (zh) 2018-02-01
CN116515757A (zh) 2023-08-01
WO2017184832A1 (en) 2017-10-26
CA3015389A1 (en) 2017-10-26
IL262266B2 (en) 2025-01-01
US20230130799A1 (en) 2023-04-27
JP2025188169A (ja) 2025-12-25
CN109195986B (zh) 2023-01-03
TWI827531B (zh) 2024-01-01
JP2019515666A (ja) 2019-06-13
JP2024023449A (ja) 2024-02-21
KR20230098361A (ko) 2023-07-03
CN109195986A (zh) 2019-01-11
JP7096770B2 (ja) 2022-07-06
KR102547738B1 (ko) 2023-06-26
JP7781128B2 (ja) 2025-12-05
MX2018012868A (es) 2019-03-11
AU2024220124A1 (en) 2024-10-17
IL262266B1 (en) 2024-09-01
KR102906454B1 (ko) 2026-01-02
KR20260011194A (ko) 2026-01-22
EA201892010A1 (ru) 2019-03-29
KR20180134893A (ko) 2018-12-19
BR112018071283A2 (pt) 2019-02-12
EP3445781A1 (en) 2019-02-27
AR109451A1 (es) 2018-12-12

Similar Documents

Publication Publication Date Title
US12503520B2 (en) Compositions and methods for making antibodies based on use of an expression-enhancing locus
US12528883B2 (en) Compositions and methods for making antibodies based on use of expression-enhancing loci
EA051643B1 (ru) Композиции и способы получения антител, основанные на применении локуса, обеспечивающего повышенную экспрессию
EA044725B1 (ru) Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию
EA046654B1 (ru) Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию
EA052803B1 (ru) Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ BABB, ROBERT; BURAKOV, DARYA; CHEN, GANG; FANDL, JAMES P. AND ZHAO, YU

FGA Letters patent sealed or granted (standard patent)